Browse News
Filter News
Found 11,511 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Laminar, Inc. Acquired by Johnson & Johnson Medtech for $400 Million Upfront with Additional Clinical and Regulatory Milestone Payments in 2024 and Beyond
11/30/2023
Santé Ventures, an early-stage healthcare and life sciences investment firm, has announced the acquisition of its Fund III portfolio company, Laminar, Inc., by Johnson & Johnson Medtech.
-
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
11/30/2023
Lexicon Pharmaceuticals, Inc. today announced that it has enrolled the first patient in PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabetic Peripheral Neuropathic Pain) studying LX9211, a potent, orally-delivered, selective, investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1).
-
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
11/29/2023
Gossamer Bio, Inc. today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors.
-
The agency on Tuesday said it is investigating the “serious risk” of T cell malignancy outcomes, including hospitalization and death, and evaluating the need for potential regulatory action.
-
Building on a previous 2021 collaboration, Bristol Myers Squibb is paying $100 million upfront for the development of five cardiovascular targets utilizing Avidity Biosciences’ antibody oligonucleotide conjugates.
-
Keep up with the regulator’s latest rulings on novel drugs and expanded indications, as the second half of 2023 promises some major milestone FDA approvals.
-
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
11/28/2023
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced a global licensing and research collaboration with Bristol Myers Squibb (NYSE: BMY) focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.
-
As companies clamor for a piece of the antibody-drug conjugate pie, experts pose the question: is it possible to replicate the success of Enhertu?
-
While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say the field is still wide open.
-
Halozyme to Present at Upcoming Investor Conferences - November 27, 2023
11/27/2023
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor meetings at the following investor conferences.
-
Be Biopharma to Present at the 35th Annual Piper Sandler Healthcare Conference
11/22/2023
Be Biopharma, Inc. today announced that Chief Executive Officer Joanne Smith-Farrell, Ph.D., will present at the 35th Annual Piper Sandler Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, November 30, 2023.
-
Relief Therapeutics Announces CEO Transition
11/22/2023
RELIEF THERAPEUTICS Holding SA announced that its current chief executive officer, Jack Weinstein, will be stepping down as part of a leadership transition.
-
The regulator has decided to hold an advisory committee meeting regarding BMS and 2seventy bio’s bid to move the CAR-T cell therapy into earlier lines of treatment, missing its previous target action date of Dec. 16.
-
Dementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck
11/21/2023
The Dementia Discovery Fund, a SV Health Investors fund specialized in pursuing transformational therapeutic approaches for dementias including Alzheimer's disease, is pleased to announce the acquisition of its portfolio company, Caraway Therapeutics, Inc. by Merck, known as MSD outside the United States and Canada.
-
Bayer’s investigational factor XIa inhibitor asundexian was inferior to BMS’ and Pfizer’s blockbuster blood thinner Eliquis (apixaban) in the Phase III OCEANIC-AF study.
-
Sickle Cell Disease Treatment Market Size to Garner Around USD 50.45 Billion by 2032
11/20/2023
The global sickle cell disease treatment market size is estimated to garner around USD 50.45 billion by 2032 and is expanding at a healthy CAGR of 35.1% from 2023 to 2032.
-
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
11/20/2023
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
-
FDA Roundup: November 17, 2023
11/17/2023
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
-
After Bristol Myers Squibb picked up Augtyro as part of its $4.1 billion takeover of Turning Point Therapeutics last year, the ROS1-positive non-small cell lung cancer drug reached the regulatory finish line on Wednesday.